EICHORPublic-registry site landscape for NCT07685808, “Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes”, a Overweight or Obesity study sponsored by Regeneron Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07685808 (registry record) |
| Study title | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes |
| Official title | A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity |
| Sponsor | Regeneron Pharmaceuticals |
| Condition(s) | Overweight or Obesity |
| Phase | PHASE2 |
| Listed sites | 0 |
| Intervention(s) | Olatorepatide, Placebo |
Patient-friendly overview of this study: eichor.com/study/NCT07685808.
Eichor generates a preliminary site-risk snapshot for NCT07685808 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Overweight or Obesity trials
More from Regeneron Pharmaceuticals
← Eichor home · All tracked trials · Overweight or Obesity studies · Weekly briefs
